StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) bonds

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Debt

Borrowings on the balance sheet, Jun 30, 2026

Immunocore reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2023

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Immunocore's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issued
2.50% convertible senior notes due 2030
Convertible
2.50%2030–
Convertible senior notes
Convertible at $95 a share
3.06%–$402.50M
Pharmakon loan––$0
Pharmakon loan, first tranche––$50.00M
Pharmakon loan, second tranche––$50.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?